TNF抑制剂通过降低疾病活动度抑制强直性脊柱炎脊柱放射学进展:瑞士临床质量管理队列结果
该研究基于瑞士临床质量管理队列中432例强直性脊柱炎患者、616个2年放射学间隔,评估TNF抑制剂对脊柱放射学进展的影响。多变量分析显示,既往使用TNF抑制剂使放射学进展风险降低50%(OR 0.50,95%CI 0.28-0.88)。敏感性分析提示该效应可能通过降低ASDAS介导(间接效应OR 0.75,95%CI 0.59-0.97)。
要点
- 既往使用TNF抑制剂与强直性脊柱炎患者脊柱放射学进展风险降低50%相关。
- TNF抑制剂对放射学进展的效应可能通过降低ASDAS疾病活动度介导。
- 调整时间变化的ASDAS后,TNF抑制剂直接效应不再显著(OR 0.61,95%CI 0.34-1.08)。
核心结论
- TNF抑制剂与强直性脊柱炎患者脊柱放射学进展减少相关,该效应似乎通过抑制疾病活动度介导。
研究设计与样本
- 瑞士临床质量管理队列中432例强直性脊柱炎患者,随访至多10年,每2年进行放射学评估,共616个放射学间隔。
- 放射学评分由两名阅片者按改良Stoke强直性脊柱炎脊柱评分(mSASSS)在已知时间顺序下进行。
- 采用二项广义估计方程模型分析2年放射学间隔前TNF抑制剂使用与间隔内进展的关系,并校正潜在混杂因素及对缺失值进行多重插补。
主要发现
- 放射学进展定义为2年内mSASSS增加≥2个单位,2年内mSASSS平均(标准差)增加0.9(2.6)个单位。
- 多变量分析中,既往使用TNF抑制剂使放射学进展的比值降低50%(OR 0.50,95%CI 0.28-0.88)。
- 在纳入时间变化ASDAS的分析中,TNF抑制剂对进展的直接效应不显著(OR 0.61,95%CI 0.34-1.08),而通过降低ASDAS的间接效应有统计学意义(OR 0.75,95%CI 0.59-0.97)。
关键数值与推荐
- 放射学进展定义为2年内mSASSS增加≥2个单位。
- mSASSS评分由两名阅片者按改良Stoke强直性脊柱炎脊柱评分在已知时间顺序下完成。
临床怎么用
- 对于强直性脊柱炎患者,使用TNF抑制剂可能通过降低疾病活动度(ASDAS)来减少脊柱放射学进展。
- 临床决策中可将控制疾病活动度作为抑制放射学进展的重要治疗目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To analyse the impact of tumour necrosis factor inhibitors (TNFis) on spinal radiographic progression in ankylosing spondylitis (AS). METHODS: Patients with AS in the Swiss Clinical Quality Management cohort with up to 10 years of follow-up and radiographic assessments every 2 years were included. Radiographs were scored by two readers according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) with known chronology. The relationship between TNFi use before a 2-year radiographic interval and progression within the interval was investigated using binomial generalised estimating equation models with adjustment for potential confounding and multiple imputation of missing values. Ankylosing Spondylitis Disease Activity Score (ASDAS) was regarded as mediating the effect of TNFi on progression and added to the model in a sensitivity analysis. RESULTS: A total of 432 patients with AS contributed to data for 616 radiographic intervals. Radiographic progression was defined as an increase in ≥2 mSASSS units in 2 years. Mean (SD) mSASSS increase was 0.9 (2.6) units in 2 years. Prior use of TNFi reduced the odds of progression by 50% (OR 0.50, 95% CI 0.28 to 0.88) in the multivariable analysis. While no direct effect of TNFi on progression was present in an analysis including time-varying ASDAS (OR 0.61, 95% CI 0.34 to 1.08), the indirect effect, via a reduction in ASDAS, was statistically significant (OR 0.75, 95% CI 0.59 to 0.97). CONCLUSION: TNFis are associated with a reduction of spinal radiographic progression in patients with AS. This effect seems mediated through the inhibiting effect of TNFi on disease activity.
引用
- Molnar C, Scherer A, Baraliakos X, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2017. PMID: 28939631. doi:10.1136/annrheumdis-2017-211544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。